Blood Test for Lung Cancer
November 9, 2021 | Terry Sharrer
From Johns Hopkins Kimmel Cancer Center: “The test approach, called DELFI (DNA evaluation of fragments for early interception), spots unique patterns in the fragmentation of DNA shed from cancer cells circulating in the bloodstream. Applying this technology to blood samples taken from 796 individuals in Denmark, the Netherlands and the U.S., investigators found that the DELFI approach accurately distinguished between patients with and without lung cancer.” MORE
Image Credit: Carolyn Hruban and Johns Hopkins Kimmel Cancer Center